DNA Testing Company Raises Funds with Strategic Chinese Partner, SGHF
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--#DNA--FitnessGenes (www.fitnessgenes.com), a pioneer in DNA testing and interpretation specializing in personalized fitness and nutrition, has just announced successful funding by strategic partner SGHF in the amount of $5 million. Based in Los Angeles and London, FitnessGenes is the first European company in the genetics sector to raise a substantial Series A round.
FitnessGenes removes the guesswork from fitness and nutrition by providing personalized plans based on complex analysis of each customer's DNA, lifestyle and environment. Examining years of peer-validated scientific research, FitnessGenes helps customers understand their genetics and put this precise knowledge into action to reach their goals most effectively.
SGHF is an Asia-Pacific partner that focuses on supporting start-ups in Life Science, Healthcare and IOT industries globally, forming strong strategic partnerships with industry leaders, listed companies and sovereign funds. SGHF has invested in startups in the biotechnology, life-sciences and healthcare sectors, as well as in Aland Nutraceutical Holding Ltd, which owns International Vitamin Corporation (IVC), one of largest supplements companies in the world.
“We are delighted to have this vote of confidence from the team at SGHF so we can continue to build the world’s most personalized fitness and nutrition platform,” says Dr. Dan Reardon, Co-founder and CEO. “Our mission is to bring transformation to millions of customers around the world who are overwhelmed and confused by the amount of choice and generic recommendations on the market.”
“We highly agree with FitnessGenes’ understanding of how genetic science will change our life and are impressed with the company's innovation in the practice of applying genetics and technology to fitness and nutrition,” says Alex Liu, Managing Director of SGHF. “We look forward to working with the experienced and innovative management team to help scale FitnessGenes.”
FitnessGenes is in talks with other investors to close an additional $5 million in funding and plans to allocate their Series A round toward advancing their patent-pending platform, growing their product offering and expanding operations in North America and Europe. Together with 23andme, FitnessGenes is part of a unique consortia launched by Illumina (NASDAQ: ILMN), the global leader in DNA sequencing and array technologies, to bring its latest genotyping array into healthcare, translational research and consumer genomics.
FitnessGenes, founded by scientists Dr. Samantha Decombel and Dr. Stuart Grice, and fitness and nutrition experts Dr. Dan Reardon and Mark Gilbert, is committed to building on the foundations of its scientific and technological excellence that has attracted partnerships with top academic institutions such as the Universities of Oxford, Birmingham and Loughborough. FitnessGenes is the only fitness genetic testing company to date to have been awarded funding by the UK Government’s innovation agency, Innovate UK (formerly the Technology Strategy Board).
To learn more about FitnessGenes, visit them on the web at www.fitnessgenes.com or on social media @FitnessGenes.
FitnessGenes is the first DNA-testing platform of its kind to eliminate guesswork from fitness and nutrition. With a simple DNA test and an intricate analysis of multiple gene variations, their team of genetic scientists reveal specific traits including metabolic tendencies, dietary sensitivities, fat burning capacity, muscle type, recovery time and more. FitnessGenes then prescribes personalized, week-by-week exercise and nutrition programs based on your genetic profile and wellness goals. Featured on The Doctors, in Inc.com, InStyle, The New York Times, Men's Fitness, Shape, SELF and more, FitnessGenes has received notable awards from the UK government and is working with several prestigious academic institutions to further their scientific innovation. Billions of possibilities -- only one you. www.fitnessgenes.com
SGHF is founded in 2016 focusing on investment in growing enterprises of Industry 4.0, IOT industry, Healthcare, Life Science and other high-tech industries in a global context. SGHF has strategic partnerships with listed companies in related industries, state-backed investment funds and financial groups. With its capital and industry resources, SGHF also supports overseas companies' market entry and expansion in Asia Pacific as well as their globalization strategies.